These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34029010)

  • 1. Enhanced Delivery of Neuroactive Drugs via Nasal Delivery with a Self-Healing Supramolecular Gel.
    Wang JT; Rodrigo AC; Patterson AK; Hawkins K; Aly MMS; Sun J; Al Jamal KT; Smith DK
    Adv Sci (Weinh); 2021 Jul; 8(14):e2101058. PubMed ID: 34029010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery.
    Sharma S; Lohan S; Murthy RS
    Drug Dev Ind Pharm; 2014 Jul; 40(7):869-78. PubMed ID: 23600649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.
    Kao HD; Traboulsi A; Itoh S; Dittert L; Hussain A
    Pharm Res; 2000 Aug; 17(8):978-84. PubMed ID: 11028945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery.
    Salatin S; Barar J; Barzegar-Jalali M; Adibkia K; Milani MA; Jelvehgari M
    Arch Pharm Res; 2016 Sep; 39(9):1181-92. PubMed ID: 27352214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and evaluation of levodopa methyl ester intranasal delivery systems.
    Chun IK; Lee YH; Lee KE; Gwak HS
    J Parkinsons Dis; 2011; 1(1):101-7. PubMed ID: 23939261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
    Chao OY; Mattern C; Silva AM; Wessler J; Ruocco LA; Nikolaus S; Huston JP; Pum ME
    Brain Res Bull; 2012 Feb; 87(2-3):340-5. PubMed ID: 22108632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel formulations and modes of delivery of levodopa.
    Poewe W; Antonini A
    Mov Disord; 2015 Jan; 30(1):114-20. PubMed ID: 25476691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson's disease.
    Rao M; Agrawal DK; Shirsath C
    Drug Dev Ind Pharm; 2017 Jan; 43(1):142-150. PubMed ID: 27533244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa delivery systems: advancements in delivery of the gold standard.
    Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
    Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery.
    Hao J; Zhao J; Zhang S; Tong T; Zhuang Q; Jin K; Chen W; Tang H
    Colloids Surf B Biointerfaces; 2016 Nov; 147():376-386. PubMed ID: 27566226
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Arisoy S; Sayiner O; Comoglu T; Onal D; Atalay O; Pehlivanoglu B
    Pharm Dev Technol; 2020 Jul; 25(6):735-747. PubMed ID: 32141798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piribedil loaded thermo-responsive nasal in situ gelling system for enhanced delivery to the brain: formulation optimization, physical characterization, and in vitro and in vivo evaluation.
    Uppuluri CT; Ravi PR; Dalvi AV; Shaikh SS; Kale SR
    Drug Deliv Transl Res; 2021 Jun; 11(3):909-926. PubMed ID: 32514705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ nasal gel drug delivery: A novel approach for brain targeting through the mucosal membrane.
    Kaur P; Garg T; Rath G; Goyal AK
    Artif Cells Nanomed Biotechnol; 2016 Jun; 44(4):1167-76. PubMed ID: 25749276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal delivery of insulin by self-emulsified nanoemulsion system: In vitro and in vivo studies.
    Shah D; Guo Y; Ban I; Shao J
    Int J Pharm; 2022 Mar; 616():121565. PubMed ID: 35150847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.
    Kim TK; Kang W; Chun IK; Oh SY; Lee YH; Gwak HS
    Eur J Pharm Sci; 2009 Dec; 38(5):525-32. PubMed ID: 19804823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal delivery of ciprofloxacin to rats: A topical approach using a thermoreversible in situ gel.
    Sousa J; Alves G; Oliveira P; Fortuna A; Falcão A
    Eur J Pharm Sci; 2017 Jan; 97():30-37. PubMed ID: 27810560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration.
    Brime B; Ballesteros MP; Frutos P
    J Microencapsul; 2000; 17(6):777-84. PubMed ID: 11063424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.
    Lee YH; Kim KH; Yoon IK; Lee KE; Chun IK; Rhie JY; Gwak HS
    Eur J Drug Metab Pharmacokinet; 2014 Dec; 39(4):237-42. PubMed ID: 24363125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method.
    Md S; Haque S; Fazil M; Kumar M; Baboota S; Sahni JK; Ali J
    Expert Opin Drug Deliv; 2014 Jun; 11(6):827-42. PubMed ID: 24655115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal delivery system of bacterial antigen using thermosensitive hydrogels based on a Pluronic-Gantrez conjugate.
    Pastor Y; Ting I; Martínez AL; Irache JM; Gamazo C
    Int J Pharm; 2020 Apr; 579():119154. PubMed ID: 32081801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.